Replies to post #14344 on RespireRx Pharmaceuticals Inc (RSPI)

[dockside130]

The presentation was positive on highlighing the opportunities in RD and in other CNS indications. No discussion of previous problems with the FDA. He did mention they continue to look at in licensing. He reports patents are strong. Overall a upbeat short presentation will no earth shattering news.

[neuroinv]

How are M&A plans/hopes articulated in these brief presentations? For companies that look to be acquirers, the boilerplate is always 'we are always examining strategic possibilities that could help us reach our goals' etc. etc. Not a lot of detail, sometimes they'll state the general areas (e.g. psychiatric drugs) of most interest.

For those like Cortex who are not acquirers, but potential acquirees--have you ever heard a CEO say: 'We believe that the progress we have made will make us a more attractive acquisition target for other companies.."? I haven't. It's not something that can be planned for, unless you are planning a firesale.

I think Cortex would certainly listen to offers--they already do--but they feel no need to sell cheap, and their public presentation is going to continue to be one where they accentuate the ability to remain independent.

I personally could do without the inlicensing mention, but I think that is also largely boilerplate. 'We'll look, we'll listen'--but if you consider the plans laid out for 2008, the cash and personnel resources necessary for an inlicensing just aren't there. Good. They have plenty going on inhouse.

NeuroInvestment